SEC Comment Letter 0000000000-25-002445 to Altimmune, Inc. (ALT)

Altimmune, Inc.
Date: March 5, 2025 · CIK: 0001326190 · Accession: 0000000000-25-002445

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 333-285355

Date

March 5, 2025

Author

Vipin Garg

Form

UPLOAD

Company

Altimmune, Inc.

Letter

March 5, 2025 Vipin Garg Chief Executive Officer Altimmune, Inc. 910 Clopper Road, Suite 201S Gaithersburg, MD 20878 Re:Altimmune, Inc. Registration Statement on Form S-3 Filed February 27, 2025 File No. 333-285355 Dear Vipin Garg: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tyler Howes at 202-551-3370 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Joseph C. Theis, Esq.

Show Raw Text

March 5, 2025
Vipin Garg
Chief Executive Officer
Altimmune, Inc.
910 Clopper Road, Suite 201S
Gaithersburg, MD 20878
Re:Altimmune, Inc.
Registration Statement on Form S-3
Filed February 27, 2025
File No. 333-285355
Dear Vipin Garg:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Tyler Howes at 202-551-3370 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Joseph C. Theis, Esq.

SecProbe.io